A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf
.
SLFN11 informs on standard of care and novel treatments in a wide range of cancer models
2020
British Journal of Cancer
Background Schlafen 11 (SLFN11) has been linked with response to DNA-damaging agents (DDA) and PARP inhibitors. An in-depth understanding of several aspects of its role as a biomarker in cancer is missing, as is a comprehensive analysis of the clinical significance of SLFN11 as a predictive biomarker to DDA and/or DNA damage-response inhibitor (DDRi) therapies. Methods We used a multidisciplinary effort combining specific immunohistochemistry, pharmacology tests, anticancer combination
doi:10.1038/s41416-020-01199-4
pmid:33339894
pmcid:PMC7921667
fatcat:s3r3bdfykzdizbf5q2cu4rrabe